an issue – whether it be raw material shortages or cyber attacks – the faster a coordinated response can be put in place. It also makes collaboration during crises more effective because relationships and lines of communication already exist.
Michelle Tarver, Director of the FDA’ s Center for Devices and Radiological Health( CDRH), explains:“ While the vulnerabilities in the medical device supply chain are not new, we’ re growing increasingly concerned that the rise in shortages is having a significant adverse impact on neonatal and paediatric patients.”
Without adequate stakeholder input, the FDA only learns about shortages when they reach hospitals.
“Generics account for roughly 90 % of all US prescriptions and tariffs would potentially raise costs for a significant portion of the market”
ARTHUR WONG, HEALTHCARE MANAGING DIRECTOR, S & P GLOBAL RATINGS
158 June 2025